{
  "drug_name": "Cefdinir",
  "tradename": "Omnicef",
  "drug_shortage": [
    {
      "preparation": "All oral formulations",
      "start_date": "2023-06-30",
      "notes": ""
    }
  ],
  "usage_and_dosing": {
    "general": [
      "Cefdinir is an oral 3rd generation cephalosporin with enhanced activity against aerobic gram-negative bacilli, e.g., E. coli, Klebsiella sp., and P. mirabilis, as well as some oral anaerobic bacteria.",
      "Rendered inactive by extended spectrum beta-lactamases (ESBLs).",
      "Not active vs. P. aeruginosa.",
      "Used in treatment of pharyngitis, sinusitis, otitis media and uncomplicated skin and skin structure infections; off-label use for UTI in absence of alternative (Clin Infect Dis 52(5): e103; 2011).",
      "Perspective on the use of cefdinir for common infections: J Hosp Med 2024 June 2 [ahead of print].",
      "For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."
    ],
    "adult_dose": {
      "usual_dose": "300 mg po q12h or 600 mg po q24h"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "14 mg/kg/day (divided q12-24h)",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "1.7",
    "half_life_esrd": "16",
    "dose_renal_function_normal": "300 mg po q12h",
    "crcl_or_egfr": "CrCl ≥30: No dosage adjustment. CrCl <30: 300 mg q24h",
    "hemodialysis": "300 mg q48h (AD on dialysis days)",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Treatment stopped due to adverse effects (3%), rash (rare), neutropenia (rare), eosinophilia (rare), GI (3%), diarrhea (15%), C. difficile colitis, increased LFTs (1%), increased BUN/Creatinine (rare), headache (2%).",
    "Cefdinir-associated red stools in up to 1% of patients. Occurs if co-administered with iron-fortified infant formula or iron supplement. Thought to be due to cefdinir or metabolites combining with iron to form a nonabsorbable reddish precipitant. OK to continue cefdinir with adequate patient reassurance (Pediatr Emerg Care 2021;37:e421).",
    "For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "No data, but adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Cap (300 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)",
    "food_recommendation": "All preps ± food",
    "oral_absorption_percent": "Caps 16-21, Susp 25",
    "tmax_hr": "2-4",
    "peak_serum_conc_ug_ml": "1.6 (300 mg po, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "60-70",
    "volume_of_distribution_vd_l_kg_vf": "0.35 L/kg (V/F)",
    "avg_serum_half_life_hr": "1.7",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "7.1 (300 mg po, 0-inf)"
  },
  "major_drug_interactions": [
      {
          "drug": "Antacids (Al, Mg)",
          "effect": "↓ cefdinir",
          "management": "Stagger dosing by 2 hours"
      },
      {
          "drug": "Iron supplements",
          "effect": "↓ cefdinir",
          "management": "Stagger dosing by 2 hours"
      },
      {
          "drug": "Probenecid",
          "effect": "↑ cefdinir",
          "management": "Monitor"
      }
  ]
}
